Amodio

Bell

Benham

Boulton

Britten

Creusot

Giannoukakis

Hilkens

Hutchinson

Ioannidis

Janetzki

Jauregui-Amezaga

Knudsen

Morelli

Ten Brinke

Thomas

Van Brussel

Wren

PeerJ

Cellular therapies with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation. The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.</jats:p

Phillip Lord

Rachel Spiering

Juan C. Aguillon

Amy E. Anderson

Silke Appel

Daniel Benitez-Ribas

Anja ten Brinke

Femke Broere

Nathalie Cools

Maria Cristina Cuturi

Julie Diboll

Edward K. Geissler

Nick Giannoukakis

Silvia Gregori

S. Marieke van Ham

Staci Lattimer

Lindsay Marshall

Rachel A. Harry

James A. Hutchinson

John D. Isaacs

Irma Joosten

Cees van Kooten

Ascension Lopez Diaz de Cerio

Tatjana Nikolic

Haluk Barbaros Oral

Ljiljana Sofronic-Milosavljevic

Thomas Ritter

Paloma Riquelme

Angus W. Thomson

Massimo Trucco

Marta Vives-Pi

Eva M. Martinez-Caceres

Catharien M.U. Hilkens

Crossref

Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies

Supplemental Information 3: The 20 Questions Experiment

Supplemental Information 3: The 20 Questions Experiment

Abstract

Similar works

Full text

Available Versions

Crossref